|
PureTech Health PLC on Monday said that its founded entity, Vedanta Biosciences, has seen positive results for its lead programme, VE303. The Boston-based clinical-stage biotherapeutics company said the phase two study data confirmed that VE303 prevented recurrent Clostridioides difficile infection, compared with placebo. Clostridioides difficile is a type of bacteria that can cause diarrhoea. VE303 is a defined bacterial consortium therapeutic candidate designed for the prevention of recurrent Clostridioides difficile infection, PureTech said. Vedanta Biosciences is a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia. It is based in Cambridge, Massachusetts. Darrell Pardi, chair of the Division of Gastroenterology & Hepatology at the Mayo Clinic in Rochester, Minnesota, said: ‘The notorious difficulty of preventing recurrent CDI creates a large population of patients struggling with the condition, with few therapeutic options. VE303 provides an approach that is designed to address the underlying biology in a novel way. The clinical data to-date have been extremely promising, and we are eager to see future updates on this program as it progresses through the clinic.’ Shares in the FTSE 250-listed firm were up 1.8% at 221.50 pence on Monday morning in London. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
